Omron Healthcare (China) Co., Ltd.
Founded in 1933, Omron Group is an automation control and electronic equipment manufacturer. By continuously creating new social needs, Omron Group has more than 36,000 employees worldwide and a turnover of 773 billion yen. The products cover a wide range of fields such as industrial automation control systems, electronic components, automotive electronics, social systems, health and medical equipment, and have hundreds of thousands of varieties. Since entering China in the early 1970s, Omron has been moving forward with China's manufacturing industry, building a multi-faceted management system integrating R&D, design, production, sales and service, in order to build "safety" and "safety". "Environmental and "healthy" local society has made contributions. As early as the early 1970s, Mr. Takashi Ichimaru, then vice president of the ITC Promotion General Administration, began exchanges and cooperation with China as a representative of the economic circle. After technical exchanges in the 1970s, commissioned processing in the 1980s, direct investment and production in the 1990s. Entering the 21st century, Omron ushered in a new stage of "reinvestment and collaborative creation". As of March 2014, Greater China The district's sales reached 141.1 billion yen and its employees have exceeded 15,000. In order to realize the vision of the circulatory system business, Omron will launch the research and development of upper-arm blood sphygmomanometers and electrocardiogram analysis services equipped with electrocardiograms around the world, expanding its business to the field of "early detection and prevention of recurrence of atrial fibrillation". In addition, Omron will also create new equipment and services to support the early detection and improvement of living habit diseases that can induce hypertension and atrial fibrillation; through the development of algorithms using AI, we will be committed to early perception of disease signs and build preventive medical treatment mechanism. In China, where the number of patients with hypertension and chronic diseases is increasing, Omron will increase cooperation with doctors and medical institutions and strengthen MMC health convenience stores, a service that connects medical and family health management; in India, Omron will increase The number of Omron's product experience facilities will promote the popularization of home blood pressure measurement, and cooperate with local hospitals and partner companies to create new businesses such as blood pressure and electrocardiogram monitoring services. In order to help more people improve respiratory diseases, in addition to asthma, the respiratory system industry has also launched a business targeting COPD (Chronic Obstructive Pneumonia). In emerging countries and other places, the number of patients with respiratory diseases is growing. In addition, since the diagnostic standards have not yet reached standardization, there are also problems with diagnosis difficulties. Omron will popularize the diagnosis and treatment of respiratory diseases in countries with an incomplete medical system; and in developed countries where medical expenses continue to rise, Omron will promote the popularization of treatment and symptom management support services, committed to reducing doctors, patients and their families. the burden of treatment. Pain management career will challenge “with the help of new TENS (Percutaneous Electric Stimulation Neurotherapy) technology, developing new equipment” and “sports therapy support services”, Omron makes as many people as possible without fear of pain and can do the same way they like. Carry out daily life.
Omron Healthcare (China) Co., Ltd.
Founded in 1933, Omron Group is an automation control and electronic equipment manufacturer. By continuously creating new social needs, Omron Group has more than 36,000 employees worldwide and a turnover of 773 billion yen. The products cover a wide range of fields such as industrial automation control systems, electronic components, automotive electronics, social systems, health and medical equipment, and have hundreds of thousands of varieties. Since entering China in the early 1970s, Omron has been moving forward with China's manufacturing industry, building a multi-faceted management system integrating R&D, design, production, sales and service, in order to build "safety" and "safety". "Environmental and "healthy" local society has made contributions. As early as the early 1970s, Mr. Takashi Ichimaru, then vice president of the ITC Promotion General Administration, began exchanges and cooperation with China as a representative of the economic circle. After technical exchanges in the 1970s, commissioned processing in the 1980s, direct investment and production in the 1990s. Entering the 21st century, Omron ushered in a new stage of "reinvestment and collaborative creation". As of March 2014, Greater China The district's sales reached 141.1 billion yen and its employees have exceeded 15,000. In order to realize the vision of the circulatory system business, Omron will launch the research and development of upper-arm blood sphygmomanometers and electrocardiogram analysis services equipped with electrocardiograms around the world, expanding its business to the field of "early detection and prevention of recurrence of atrial fibrillation". In addition, Omron will also create new equipment and services to support the early detection and improvement of living habit diseases that can induce hypertension and atrial fibrillation; through the development of algorithms using AI, we will be committed to early perception of disease signs and build preventive medical treatment mechanism. In China, where the number of patients with hypertension and chronic diseases is increasing, Omron will increase cooperation with doctors and medical institutions and strengthen MMC health convenience stores, a service that connects medical and family health management; in India, Omron will increase The number of Omron's product experience facilities will promote the popularization of home blood pressure measurement, and cooperate with local hospitals and partner companies to create new businesses such as blood pressure and electrocardiogram monitoring services. In order to help more people improve respiratory diseases, in addition to asthma, the respiratory system industry has also launched a business targeting COPD (Chronic Obstructive Pneumonia). In emerging countries and other places, the number of patients with respiratory diseases is growing. In addition, since the diagnostic standards have not yet reached standardization, there are also problems with diagnosis difficulties. Omron will popularize the diagnosis and treatment of respiratory diseases in countries with an incomplete medical system; and in developed countries where medical expenses continue to rise, Omron will promote the popularization of treatment and symptom management support services, committed to reducing doctors, patients and their families. the burden of treatment. Pain management career will challenge “with the help of new TENS (Percutaneous Electric Stimulation Neurotherapy) technology, developing new equipment” and “sports therapy support services”, Omron makes as many people as possible without fear of pain and can do the same way they like. Carry out daily life.
Shenzhen Yibainian Investment Industrial Co., Ltd.
Shenzhen Yi Bonian Investment Sandwich Industry Co., Ltd. is a high-tech innovative enterprise focusing on the research and development, manufacturing, sales, and service of hydrogen health products. Focusing on the core of the big health industry, expanding human health, and serving the world are the goal pursued by the Yi Bonian people. The company has a core and high-quality R&D team, focusing on the development of software and hardware for hydrogen molecular health products. He is proficient in the R&D, design, and production of snow energy equipment products, and is committed to guiding the direction of hydrogen molecular products. With the responsibility of serving public health and the leading role of innovation and technology, we always pursue high-quality products and services. Provide customers with convenient and reliable services online and offline, public health, hydrogen pine realization, hydrogen care, and healthy life, so that hydrogen energy series products can benefit the public for a better life.
Shenzhen Yibainian Investment Industrial Co., Ltd.
Shenzhen Yi Bonian Investment Sandwich Industry Co., Ltd. is a high-tech innovative enterprise focusing on the research and development, manufacturing, sales, and service of hydrogen health products. Focusing on the core of the big health industry, expanding human health, and serving the world are the goal pursued by the Yi Bonian people. The company has a core and high-quality R&D team, focusing on the development of software and hardware for hydrogen molecular health products. He is proficient in the R&D, design, and production of snow energy equipment products, and is committed to guiding the direction of hydrogen molecular products. With the responsibility of serving public health and the leading role of innovation and technology, we always pursue high-quality products and services. Provide customers with convenient and reliable services online and offline, public health, hydrogen pine realization, hydrogen care, and healthy life, so that hydrogen energy series products can benefit the public for a better life.
Johnson & Johnson (China) Investment Co., Ltd.
Johnson & Johnson Medical Technology’s global history can be traced back to the beginning of Johnson & Johnson’s establishment in the United States in 1886. As one of the healthcare companies with wide business worldwide, Johnson & Johnson originated from the production of sterile surgical sutures and auxiliary materials. For more than a century, Johnson & Johnson Medical Technology has always been committed to becoming a world-leading medical technology innovator and bringing far-reaching significance to human health with rich and diverse professional accumulation, mission-significant scientific innovation, and high enthusiasm for human health. Influence, let people all over the world have a healthy and beautiful life. At present, in the fields of surgery, cardiovascular and professional solutions, orthopedics and ophthalmology, Johnson & Johnson Medical Technology continues to innovate and deepen its efforts around the world, striving to solve unmet medical needs, reimagine the future of human health, and allow medical solutions to Smarter, more minimally invasive, more personalized, protect life and light up every beam of hope. In 1994, Johnson & Johnson Medical Technology entered the Chinese market. Currently, Johnson & Johnson Medical Technology has more than 5,000 employees in China, of which 85% are new generation employees. It is headquartered in Shanghai and has offices in Beijing, Guangzhou and other places. On the road of growing together with China's medical and health industry, we will continue to expand and improve our product layout and supply chain production capacity in China. At present, medical technology has become Johnson & Johnson's largest business segment in China. In recent years, Johnson & Johnson Medical Technology has continued to deepen its layout of end-to-end supply chain systems in China, improve local intelligent manufacturing capabilities, introduce global advanced product, technology and quality management experience, and help the industry develop at a high quality and high speed. The integrated supply chain production base located in Suzhou Industrial Park is a large comprehensive industrial park of Johnson & Johnson Medical Technology in China. It integrates the research and development and manufacturing of medical equipment, technological innovation and cooperation, global shared services, regional procurement and supplier management. and other diversified business functions, among which the intelligent manufacturing factory produces a series of innovative products such as surgery and orthopedics, responds to local demand and supplies globally. Johnson & Johnson Medical Technology not only focuses on cultivating and upgrading local intelligent manufacturing capabilities, but also further focuses on local R&D and innovation capabilities. In addition to Suzhou Supply Chain Base, Guangzhou Beixiu Biotechnology Co., Ltd., a wholly-owned subsidiary of Johnson & Johnson, is a biotechnology company specializing in technology development, research and production of pig-derived biological products. Beixiu independently developed the technology to extract fibrinogen and thrombin from mammalian blood, which is the world's first biomedical innovation. On the road to growing together with China's medical and healthcare industry, Johnson & Johnson Medical Technology has deepened the professional education and training of Chinese professional medical staff and is committed to becoming a trustworthy partner of Chinese medical staff. In line with the purpose of "exploring human technology and caring about human health", three Johnson & Johnson Medical Technology Professional Education Academic Centers located in Beijing, Shanghai and Boao Lecheng Medical Pilot Zone and the digital doctor training and education platform "Ling Yimai" provide professional knowledge, Training to adapt to China's medical service environment and innovative medical education forms will be promoted to the professional and systematic development of continuing medical education. In addition, Johnson & Johnson Medical Technology is also actively working with partners from all walks of life to promote innovation cooperation, accelerate the transformation of innovative results, and serve patients. As part of Johnson & Johnson's China Innovation Engine Strategy, Johnson & Johnson cooperates with local companies to leverage digital technologies such as artificial intelligence, surgical robots, and big data to assist doctors in more effective perioperative work and establish localized digital surgical solutions.
Johnson & Johnson (China) Investment Co., Ltd.
Johnson & Johnson Medical Technology’s global history can be traced back to the beginning of Johnson & Johnson’s establishment in the United States in 1886. As one of the healthcare companies with wide business worldwide, Johnson & Johnson originated from the production of sterile surgical sutures and auxiliary materials. For more than a century, Johnson & Johnson Medical Technology has always been committed to becoming a world-leading medical technology innovator and bringing far-reaching significance to human health with rich and diverse professional accumulation, mission-significant scientific innovation, and high enthusiasm for human health. Influence, let people all over the world have a healthy and beautiful life. At present, in the fields of surgery, cardiovascular and professional solutions, orthopedics and ophthalmology, Johnson & Johnson Medical Technology continues to innovate and deepen its efforts around the world, striving to solve unmet medical needs, reimagine the future of human health, and allow medical solutions to Smarter, more minimally invasive, more personalized, protect life and light up every beam of hope. In 1994, Johnson & Johnson Medical Technology entered the Chinese market. Currently, Johnson & Johnson Medical Technology has more than 5,000 employees in China, of which 85% are new generation employees. It is headquartered in Shanghai and has offices in Beijing, Guangzhou and other places. On the road of growing together with China's medical and health industry, we will continue to expand and improve our product layout and supply chain production capacity in China. At present, medical technology has become Johnson & Johnson's largest business segment in China. In recent years, Johnson & Johnson Medical Technology has continued to deepen its layout of end-to-end supply chain systems in China, improve local intelligent manufacturing capabilities, introduce global advanced product, technology and quality management experience, and help the industry develop at a high quality and high speed. The integrated supply chain production base located in Suzhou Industrial Park is a large comprehensive industrial park of Johnson & Johnson Medical Technology in China. It integrates the research and development and manufacturing of medical equipment, technological innovation and cooperation, global shared services, regional procurement and supplier management. and other diversified business functions, among which the intelligent manufacturing factory produces a series of innovative products such as surgery and orthopedics, responds to local demand and supplies globally. Johnson & Johnson Medical Technology not only focuses on cultivating and upgrading local intelligent manufacturing capabilities, but also further focuses on local R&D and innovation capabilities. In addition to Suzhou Supply Chain Base, Guangzhou Beixiu Biotechnology Co., Ltd., a wholly-owned subsidiary of Johnson & Johnson, is a biotechnology company specializing in technology development, research and production of pig-derived biological products. Beixiu independently developed the technology to extract fibrinogen and thrombin from mammalian blood, which is the world's first biomedical innovation. On the road to growing together with China's medical and healthcare industry, Johnson & Johnson Medical Technology has deepened the professional education and training of Chinese professional medical staff and is committed to becoming a trustworthy partner of Chinese medical staff. In line with the purpose of "exploring human technology and caring about human health", three Johnson & Johnson Medical Technology Professional Education Academic Centers located in Beijing, Shanghai and Boao Lecheng Medical Pilot Zone and the digital doctor training and education platform "Ling Yimai" provide professional knowledge, Training to adapt to China's medical service environment and innovative medical education forms will be promoted to the professional and systematic development of continuing medical education. In addition, Johnson & Johnson Medical Technology is also actively working with partners from all walks of life to promote innovation cooperation, accelerate the transformation of innovative results, and serve patients. As part of Johnson & Johnson's China Innovation Engine Strategy, Johnson & Johnson cooperates with local companies to leverage digital technologies such as artificial intelligence, surgical robots, and big data to assist doctors in more effective perioperative work and establish localized digital surgical solutions.
Henan Kang'anbei Medical Technology Co., Ltd.
Germany Kanganbei Medical (Hong Kong) Industrial Co., Ltd. is a branch of Kanganbei brand in the Asia-Pacific region. It is mainly aimed at mainland Chinese users. Adhering to Kanganbei’s “Kangan Volkswagen” concept, it is committed to the technical development of home health care products and Promote and continuously develop new technologies and launch new products to bring consumers a safe and secure high-quality life. Kang'anbei is well aware of the importance of product innovation. The products that Kang'anbei can bring to customers' health are directly closely related to the design and development team of the entire company. To this end, the company not only actively uses its own designers to develop new products and improve the existing design team, but also conducts strategic cooperation with industry companies. Relying on the industry's cutting-edge R&D advantages and advanced testing instruments, it has been successfully developed and put into production. More than a dozen household ventilators, electronic blood pressure monitors, personal hearing aids, varicose veins, and blood sugar testers, covering high, medium and low-end home health and self-health products. Kang'anbei Production Factory has an advanced 10,000-level purification production workshop, and the workshop has an advanced production line in the industry. The factory is equipped with complete assembly and testing instruments to ensure that the products produced are good products. Quality is life. The company is well aware of the importance of quality of home health care and self-health products. Making a good product requires the cooperation of the team, standardized operations and advanced instrument testing. For this reason, the company requires all employees to actively participate in ISO9001:2008 construction of quality management system. The company requires all departments to strictly follow the procedures stipulated in the quality management system during production, and requires all employees to have a continuous improvement mentality, and hold a quality management seminar every month to allow all employees to participate in the quality management system. The construction of the company ensures that the quality of the company's products is satisfactory and reassured. At present, the home health care and self-health medical products produced by Kang'anbei have been certified by relevant national medical institutions. Since the founding of the brand, Kang'anbei has followed the development policy of "people-oriented, continuous innovation, quality priority, and professional service". All rules and regulations have been improved and implemented, and the company's management and technical level have been further improved. , further enriched products, further improved quality, and further expanded market share. In today's market environment, Kang'anbei employees are full of confidence, paying attention to the long-term development of home health and self-health fields, focusing on the different needs of consumers, focusing on every detail, and providing high-quality and cost-effective products to repay consumption Those who move towards a brilliant tomorrow with steady pace.
Henan Kang'anbei Medical Technology Co., Ltd.
Germany Kanganbei Medical (Hong Kong) Industrial Co., Ltd. is a branch of Kanganbei brand in the Asia-Pacific region. It is mainly aimed at mainland Chinese users. Adhering to Kanganbei’s “Kangan Volkswagen” concept, it is committed to the technical development of home health care products and Promote and continuously develop new technologies and launch new products to bring consumers a safe and secure high-quality life. Kang'anbei is well aware of the importance of product innovation. The products that Kang'anbei can bring to customers' health are directly closely related to the design and development team of the entire company. To this end, the company not only actively uses its own designers to develop new products and improve the existing design team, but also conducts strategic cooperation with industry companies. Relying on the industry's cutting-edge R&D advantages and advanced testing instruments, it has been successfully developed and put into production. More than a dozen household ventilators, electronic blood pressure monitors, personal hearing aids, varicose veins, and blood sugar testers, covering high, medium and low-end home health and self-health products. Kang'anbei Production Factory has an advanced 10,000-level purification production workshop, and the workshop has an advanced production line in the industry. The factory is equipped with complete assembly and testing instruments to ensure that the products produced are good products. Quality is life. The company is well aware of the importance of quality of home health care and self-health products. Making a good product requires the cooperation of the team, standardized operations and advanced instrument testing. For this reason, the company requires all employees to actively participate in ISO9001:2008 construction of quality management system. The company requires all departments to strictly follow the procedures stipulated in the quality management system during production, and requires all employees to have a continuous improvement mentality, and hold a quality management seminar every month to allow all employees to participate in the quality management system. The construction of the company ensures that the quality of the company's products is satisfactory and reassured. At present, the home health care and self-health medical products produced by Kang'anbei have been certified by relevant national medical institutions. Since the founding of the brand, Kang'anbei has followed the development policy of "people-oriented, continuous innovation, quality priority, and professional service". All rules and regulations have been improved and implemented, and the company's management and technical level have been further improved. , further enriched products, further improved quality, and further expanded market share. In today's market environment, Kang'anbei employees are full of confidence, paying attention to the long-term development of home health and self-health fields, focusing on the different needs of consumers, focusing on every detail, and providing high-quality and cost-effective products to repay consumption Those who move towards a brilliant tomorrow with steady pace.
Tianjin iHealth Medical Instruments Co., Ltd.
iHealth, founded in Silicon Valley, USA in 2011, is an independent innovative mobile Internet brand under Jiuan Medical. The company launched a mobile Internet blood pressure monitor connected to Apple mobile phones, which received strong support from Apple in the United States and entered Apple's online official website and offline store channels. The company launches new products at the rate of 2-3 mobile Internet products every year, covering the fields of body temperature, blood pressure, blood sugar, blood oxygen, electrocardiogram, heart rate, weight, body fat, sleep, exercise, etc. The company integrates smart hardware, mobile applications and cloud services to form an ecosystem of personal health management.
Tianjin iHealth Medical Instruments Co., Ltd.
iHealth, founded in Silicon Valley, USA in 2011, is an independent innovative mobile Internet brand under Jiuan Medical. The company launched a mobile Internet blood pressure monitor connected to Apple mobile phones, which received strong support from Apple in the United States and entered Apple's online official website and offline store channels. The company launches new products at the rate of 2-3 mobile Internet products every year, covering the fields of body temperature, blood pressure, blood sugar, blood oxygen, electrocardiogram, heart rate, weight, body fat, sleep, exercise, etc. The company integrates smart hardware, mobile applications and cloud services to form an ecosystem of personal health management.
Zhejiang Jiatuo Medical Instrument Technology Co., Ltd.
Zhejiang Jiantuo Medical Instrument Technology Co., Ltd. is headquartered in Yuhang National Economic Development Zone, Hangzhou City, Zhejiang Province, covering an area of 130 acres and owns American branches overseas. It is a high-tech enterprise integrating scientific research, development, production, sales and customer service, specializing in the research, development, and sales of home electronic medical products. Since its establishment in 2002, in line with the business philosophy of "leading technology, quality first, advanced management, and excellent service", it has successively developed and produced electronic thermometers, electronic blood pressure meters, infrared forehead thermometers, infrared ear thermometers, blood glucose meters, and blood sugar. 14 series of products including test strips, breast pumps, insulin pumps, injection/infusion pumps, new crown test strips (colloidal gold method), DOA drug test strips, hemoglobin instruments, hemoglobin test strips, POCT other biochemical products. Jiantuo Medical's business covers more than 100 countries and regions around the world, and its products have obtained multiple global market access licenses, such as: domestic CFDA registration certificate, CE, FDA, MDSAP, Brazil certification, etc. At the same time, with OEM, ODM and private brand marketing models, it is sold to distributors, OTC chain pharmacies, hospitals and other offline channels in various provinces and cities across the country, as well as online platforms such as Tmall, JD.com, Suning, and Pinduoduo. Enjoy a good reputation in the market. The company has a dedicated R&D center and factory, standardized experimental center and first-class production equipment and the implementation of ISO13485 quality system, providing reliable guarantees for product R&D and production quality. Jiantuo Medical has multiple independent brands such as "SEJOY Shijia", "SEJOY Shijie", "JOYTECH Jiantuo", "Jiantuo Jia", and "Jiantuo Medical". The annual sales in 2020 reached 1.6 billion yuan. The annual output of 400 million POCT instant diagnostic test strips is 56 million units per year. In the future, the company will increase its investment in scientific research and produce more technological, innovative, more humane and intelligent adaptable household medical device products. It will serve tens of millions of families through complete online and offline channels, and is committed to creating worthwhile. A world-class home medical device brand trusted by consumers.
Zhejiang Jiatuo Medical Instrument Technology Co., Ltd.
Zhejiang Jiantuo Medical Instrument Technology Co., Ltd. is headquartered in Yuhang National Economic Development Zone, Hangzhou City, Zhejiang Province, covering an area of 130 acres and owns American branches overseas. It is a high-tech enterprise integrating scientific research, development, production, sales and customer service, specializing in the research, development, and sales of home electronic medical products. Since its establishment in 2002, in line with the business philosophy of "leading technology, quality first, advanced management, and excellent service", it has successively developed and produced electronic thermometers, electronic blood pressure meters, infrared forehead thermometers, infrared ear thermometers, blood glucose meters, and blood sugar. 14 series of products including test strips, breast pumps, insulin pumps, injection/infusion pumps, new crown test strips (colloidal gold method), DOA drug test strips, hemoglobin instruments, hemoglobin test strips, POCT other biochemical products. Jiantuo Medical's business covers more than 100 countries and regions around the world, and its products have obtained multiple global market access licenses, such as: domestic CFDA registration certificate, CE, FDA, MDSAP, Brazil certification, etc. At the same time, with OEM, ODM and private brand marketing models, it is sold to distributors, OTC chain pharmacies, hospitals and other offline channels in various provinces and cities across the country, as well as online platforms such as Tmall, JD.com, Suning, and Pinduoduo. Enjoy a good reputation in the market. The company has a dedicated R&D center and factory, standardized experimental center and first-class production equipment and the implementation of ISO13485 quality system, providing reliable guarantees for product R&D and production quality. Jiantuo Medical has multiple independent brands such as "SEJOY Shijia", "SEJOY Shijie", "JOYTECH Jiantuo", "Jiantuo Jia", and "Jiantuo Medical". The annual sales in 2020 reached 1.6 billion yuan. The annual output of 400 million POCT instant diagnostic test strips is 56 million units per year. In the future, the company will increase its investment in scientific research and produce more technological, innovative, more humane and intelligent adaptable household medical device products. It will serve tens of millions of families through complete online and offline channels, and is committed to creating worthwhile. A world-class home medical device brand trusted by consumers.
Changzhou Weipu Medical Devices Co., Ltd.
Changzhou Weipu Medical Devices Co., Ltd. is located in Xinbei District Changzhou City, in the Golden Triangle of the Yangtze River, here we have superior geographical location and convenient transportation.The company covers an area of over 20000 square meters and is dedicated to the research and development, production, sales, and service of medical devices.
As one of the largest OEM manufacturer in China, we achieve full inspection of each product and specification, with a large workload every time. We have a strong commitment to healthcare professionals, and we are proving it every day. Although it is time-consuming and labor-intensive, and increases costs, the quality reputation of Weipu brand has won recognition from the market and customers.
Our company adheres to the corporate philosophy of "customer first, technological innovation, reliable quality", and has a large number of professional talents, laying a solid foundation for the company to continuously surpass and pursue better goals. The company actively follows the ISO13485 quality management system, strictly manages quality, ensures product quality, provides trustworthy products for users, and receives recognition from the majority of users with the most thoughtful service.
Healthcare professionals inspire our wound management, prevention and surgical solutions. Their relentless search for new and better ways to care for patients drives us to innovate. And the research and development of new products is the source of maintaining a company's market advantage and competitiveness. Therefore, we always insist on paying tribute to life with innovation, patient safety first and clinical effect first.
Changzhou Weipu Medical Devices Co., Ltd.
Changzhou Weipu Medical Devices Co., Ltd. is located in Xinbei District Changzhou City, in the Golden Triangle of the Yangtze River, here we have superior geographical location and convenient transportation.The company covers an area of over 20000 square meters and is dedicated to the research and development, production, sales, and service of medical devices.
As one of the largest OEM manufacturer in China, we achieve full inspection of each product and specification, with a large workload every time. We have a strong commitment to healthcare professionals, and we are proving it every day. Although it is time-consuming and labor-intensive, and increases costs, the quality reputation of Weipu brand has won recognition from the market and customers.
Our company adheres to the corporate philosophy of "customer first, technological innovation, reliable quality", and has a large number of professional talents, laying a solid foundation for the company to continuously surpass and pursue better goals. The company actively follows the ISO13485 quality management system, strictly manages quality, ensures product quality, provides trustworthy products for users, and receives recognition from the majority of users with the most thoughtful service.
Healthcare professionals inspire our wound management, prevention and surgical solutions. Their relentless search for new and better ways to care for patients drives us to innovate. And the research and development of new products is the source of maintaining a company's market advantage and competitiveness. Therefore, we always insist on paying tribute to life with innovation, patient safety first and clinical effect first.
"We will make every diabetic patient in China have his own blood sugar meter." With this dream in mind, Sannuo Bio was founded in 2002, embarking on the journey of promoting economical and affordable blood sugar monitoring products in China and developing the local diabetes health industry. Adhering to the core values of "No for Love", Sannuo Bio has always been committed to innovation in biosensing technology, developing, producing and selling a series of rapid diagnostic and testing products for patients with chronic diseases and medical and health professionals. Since its establishment, Sanno blood glucose meter, characterized by "accuracy, simplicity and economical", has received unanimous praise from Chinese consumers. In China, more than 50% of diabetic patients use Sannuo's products. The company can proudly claim that the company has successfully promoted the popularization of blood glucose meters in China and the self-glycemic management results of Chinese diabetic patients. However, giving diabetics a blood glucose meter is only the company's first step. In order to achieve the goal of effectively controlling blood sugar levels, diabetic patients need to systematically learn related knowledge such as blood sugar monitoring, diet, and exercise. Therefore, the company is actively expanding into the field of diabetes medical services, creating a "hardware + software + service" model to help diabetic patients understand and master comprehensive diabetes management, and move towards the goal of "from promoter of blood glucose meters to diabetes digital management experts" . This goal inspired every Sannuo employee. From this, the company provided a more advanced blood sugar monitoring system, developed a multi-analyte analyzer to provide more diabetes-related information, and launched a hospital diabetes management platform. , create a closed loop between doctors, patients, nutritionists and diabetes educators. In September 2014, they all acquired Beijing Sannuojianheng Diabetes Hospital and launched a pilot program in the field of diabetes medical services; in January 2016, they participated in the acquisition of Trividia Health Inc, the United States, taking the first step of internationalization, and entering the The frontier of the global blood glucose meter industry; in July 2016, it acquired Polymer Technology Systems, Inc., a joint venture with external strategic investors, actively expanding its POCT detection business and providing a more comprehensive overall solution for chronic disease prevention and control. Ultimately, the company will form an ecosystem of diabetes management, providing a systematic solution to improve the quality of life of diabetic patients, reduce the communication costs between health care providers and patients, and improve the social health care economy.
Sinocare Inc.
"We will make every diabetic patient in China have his own blood sugar meter." With this dream in mind, Sannuo Bio was founded in 2002, embarking on the journey of promoting economical and affordable blood sugar monitoring products in China and developing the local diabetes health industry. Adhering to the core values of "No for Love", Sannuo Bio has always been committed to innovation in biosensing technology, developing, producing and selling a series of rapid diagnostic and testing products for patients with chronic diseases and medical and health professionals. Since its establishment, Sanno blood glucose meter, characterized by "accuracy, simplicity and economical", has received unanimous praise from Chinese consumers. In China, more than 50% of diabetic patients use Sannuo's products. The company can proudly claim that the company has successfully promoted the popularization of blood glucose meters in China and the self-glycemic management results of Chinese diabetic patients. However, giving diabetics a blood glucose meter is only the company's first step. In order to achieve the goal of effectively controlling blood sugar levels, diabetic patients need to systematically learn related knowledge such as blood sugar monitoring, diet, and exercise. Therefore, the company is actively expanding into the field of diabetes medical services, creating a "hardware + software + service" model to help diabetic patients understand and master comprehensive diabetes management, and move towards the goal of "from promoter of blood glucose meters to diabetes digital management experts" . This goal inspired every Sannuo employee. From this, the company provided a more advanced blood sugar monitoring system, developed a multi-analyte analyzer to provide more diabetes-related information, and launched a hospital diabetes management platform. , create a closed loop between doctors, patients, nutritionists and diabetes educators. In September 2014, they all acquired Beijing Sannuojianheng Diabetes Hospital and launched a pilot program in the field of diabetes medical services; in January 2016, they participated in the acquisition of Trividia Health Inc, the United States, taking the first step of internationalization, and entering the The frontier of the global blood glucose meter industry; in July 2016, it acquired Polymer Technology Systems, Inc., a joint venture with external strategic investors, actively expanding its POCT detection business and providing a more comprehensive overall solution for chronic disease prevention and control. Ultimately, the company will form an ecosystem of diabetes management, providing a systematic solution to improve the quality of life of diabetic patients, reduce the communication costs between health care providers and patients, and improve the social health care economy.
Tianjin iHealth Medical Instruments Co., Ltd.
Tianjin Jiuan Medical Electronics Co., Ltd. was established in 1995. It is a listed company focusing on the research and development and production of health electronic products and smart hardware. It is also a personal health focus on building the mobile Internet "smart hardware + mobile application + cloud service" An innovative technology enterprise that manages cloud platforms. The company was listed on the Shenzhen SME Board on June 10, 2010 (stock code 002432). In the same year, it transformed into the mobile Internet and created the independent innovative brand "iHealth", and launched a mobile Internet blood pressure monitor connected to Apple mobile phones, which received strong support from Apple in the United States. , enter Apple's online official website and offline direct sales channels. The company has successively launched personal health wearable devices covering blood pressure, blood sugar, blood oxygen, electrocardiogram, heart rate, weight, body fat, sleep, exercise and other fields, and has received a US$25 million strategic investment from Xiaomi Technology, becoming a cooperation in Xiaomi's ecosystem chain. partner. The company has successively established subsidiaries in Silicon Valley, USA, Paris, Beijing and Singapore, and acquired eDevice, a leading French mobile medical company that provides device interconnection and remote monitoring services for pacemaker patients for 700 million yuan. In 2017, Jiuan Medical participated in and established an overseas merger and acquisition fund, and in the same year it acquired the US mobile medical company Care Innovations ("CI").
Tianjin iHealth Medical Instruments Co., Ltd.
Tianjin Jiuan Medical Electronics Co., Ltd. was established in 1995. It is a listed company focusing on the research and development and production of health electronic products and smart hardware. It is also a personal health focus on building the mobile Internet "smart hardware + mobile application + cloud service" An innovative technology enterprise that manages cloud platforms. The company was listed on the Shenzhen SME Board on June 10, 2010 (stock code 002432). In the same year, it transformed into the mobile Internet and created the independent innovative brand "iHealth", and launched a mobile Internet blood pressure monitor connected to Apple mobile phones, which received strong support from Apple in the United States. , enter Apple's online official website and offline direct sales channels. The company has successively launched personal health wearable devices covering blood pressure, blood sugar, blood oxygen, electrocardiogram, heart rate, weight, body fat, sleep, exercise and other fields, and has received a US$25 million strategic investment from Xiaomi Technology, becoming a cooperation in Xiaomi's ecosystem chain. partner. The company has successively established subsidiaries in Silicon Valley, USA, Paris, Beijing and Singapore, and acquired eDevice, a leading French mobile medical company that provides device interconnection and remote monitoring services for pacemaker patients for 700 million yuan. In 2017, Jiuan Medical participated in and established an overseas merger and acquisition fund, and in the same year it acquired the US mobile medical company Care Innovations ("CI").
Guangzhou Fuerle Health Technology Co., Ltd
Guangzhou Fuerle Health Technology Co., Ltd. has been focusing on the R&D and production of intelligent beauty and health products, sub-health repair and conditioning equipment for 20 years.
The company conducts cooperative research projects with the Academy of Chinese Academy of Sciences, the School of Psychology of South China Normal University, the Institute of Life Sciences of Sun Yat-sen University, and the School of Tibetan Medicine of Qinghai University.
The company has obtained CE, CB, FCC, UKCA, PSE, SAA, RoHS, FDA, ISO9001, CCC and other certifications, and has more than 100 product invention patents, appearance patents and practical patents. The products are exclusively for domestic and foreign e-commerce, Beauty and health care offline entities, brand owners, project companies and other channels are exported to more than 100 countries in Southeast Asia, Europe and the United States.
Main products: Graphene, far-infrared products, photon pemf mat, sauna dome, infrared sauna blankets, body slimming belts and other health and intelligent beauty care products.
Guangzhou Fuerle Health Technology Co., Ltd
Guangzhou Fuerle Health Technology Co., Ltd. has been focusing on the R&D and production of intelligent beauty and health products, sub-health repair and conditioning equipment for 20 years.
The company conducts cooperative research projects with the Academy of Chinese Academy of Sciences, the School of Psychology of South China Normal University, the Institute of Life Sciences of Sun Yat-sen University, and the School of Tibetan Medicine of Qinghai University.
The company has obtained CE, CB, FCC, UKCA, PSE, SAA, RoHS, FDA, ISO9001, CCC and other certifications, and has more than 100 product invention patents, appearance patents and practical patents. The products are exclusively for domestic and foreign e-commerce, Beauty and health care offline entities, brand owners, project companies and other channels are exported to more than 100 countries in Southeast Asia, Europe and the United States.
Main products: Graphene, far-infrared products, photon pemf mat, sauna dome, infrared sauna blankets, body slimming belts and other health and intelligent beauty care products.
NINGBO RAYCAREMED MEDICAL INSTRUMENTS CO., LTD
Ningbo Raycaremed Medical Instruments Co.,Ltd is one of the professional supplier for the Medical Instrument products in China. Our Team has more than 10 years experiences in Medical field. We export our products to customers in Europe, Africa, Asia and America. We are factory ,located in Jiangsu province,which near Shanghai port, we produce Syringe, infusion set, Gloves and Face mask.
In order to fulfill and increasing needs of our trusted and loyal customers,apart from our factory ,we have more than 5 strategic partners which produce urine bags, surgical gowns, medical tubes, wound dressing syringes diagnostics & lab products.
We care the success of our customers,we know that the important of quality,so we set up a strong QC team stay in differences production lines to ensure & control quality.
Our Company is approved by CE&ISO certificates for most of products.
In future, Raycaremed Medical will keep high effcient and professional for every customer, and associating company development with human health. We will keep putting love and respect into our every product all the way, and do our best effort to bring health to everyone at the world.
NINGBO RAYCAREMED MEDICAL INSTRUMENTS CO., LTD
Ningbo Raycaremed Medical Instruments Co.,Ltd is one of the professional supplier for the Medical Instrument products in China. Our Team has more than 10 years experiences in Medical field. We export our products to customers in Europe, Africa, Asia and America. We are factory ,located in Jiangsu province,which near Shanghai port, we produce Syringe, infusion set, Gloves and Face mask.
In order to fulfill and increasing needs of our trusted and loyal customers,apart from our factory ,we have more than 5 strategic partners which produce urine bags, surgical gowns, medical tubes, wound dressing syringes diagnostics & lab products.
We care the success of our customers,we know that the important of quality,so we set up a strong QC team stay in differences production lines to ensure & control quality.
Our Company is approved by CE&ISO certificates for most of products.
In future, Raycaremed Medical will keep high effcient and professional for every customer, and associating company development with human health. We will keep putting love and respect into our every product all the way, and do our best effort to bring health to everyone at the world.
Beijing Yicheng Bio - Electronics Technology Co., Ltd.
Beijing Yicheng Bioelectronics Technology Co., Ltd. was established in 1993. It is an excellent domestic blood glucose meter manufacturer, a national high-tech enterprise, Zhongguancun high-tech enterprise, a national technology research and development plan (863 plan ) support enterprise, and China medical rapid testing. Professional manufacturers in the field. The company's main business is the research, development, production and sales of in vitro diagnostic rapid testing products (including instruments and in vitro diagnostic reagents) for diabetes and complications, and provides them with comprehensive personal health management services related to it. The company comprehensively uses electrochemical biosensor technology, immunolabeling chromatography technology and human sign detection technology to form a blood sugar monitoring system, mainly blood ketone body test, blood uric acid test, urine microalbumin test, card-type electrocardiogram A rich product line supplemented by detectors and other products. At the same time, the company also has some health products production and sales business, and its main products are Yicheng Pure Cordyceps mycelium capsules, etc. In addition to the above products, the company has begun to operate the online chronic disease management platform - Yicheng Network Hospital, expanding its business to the downstream health service field. The Yicheng Network Hospital built by the company aims to use Internet technology to connect equipment with medical service resources and provide online personal comprehensive health management services for patients with chronic diseases. Since its establishment, Yicheng Bio has been committed to relying on continuous technological development to provide diverse and advanced rapid testing products to all sectors of society, constantly meeting human pursuit of health. The company's doctoral, master's and engineer teams carry out independent research and development work. The technical team members graduated from Tsinghua University, Peking University, Academy of Military Medical Sciences, University of Chinese Academy of Sciences, University of Bochum, University of Saskatchewan, and other well-known domestic and foreign universities. They have long been Engaged in the research and development of electrochemical biosensor technology, gold standard immunochromatography technology, biochip technology, biochemical analysis kits, antibody reagents and other fields. The company has complete independent intellectual property rights in various core technical links and owns a total of 26 patents.
Beijing Yicheng Bio - Electronics Technology Co., Ltd.
Beijing Yicheng Bioelectronics Technology Co., Ltd. was established in 1993. It is an excellent domestic blood glucose meter manufacturer, a national high-tech enterprise, Zhongguancun high-tech enterprise, a national technology research and development plan (863 plan ) support enterprise, and China medical rapid testing. Professional manufacturers in the field. The company's main business is the research, development, production and sales of in vitro diagnostic rapid testing products (including instruments and in vitro diagnostic reagents) for diabetes and complications, and provides them with comprehensive personal health management services related to it. The company comprehensively uses electrochemical biosensor technology, immunolabeling chromatography technology and human sign detection technology to form a blood sugar monitoring system, mainly blood ketone body test, blood uric acid test, urine microalbumin test, card-type electrocardiogram A rich product line supplemented by detectors and other products. At the same time, the company also has some health products production and sales business, and its main products are Yicheng Pure Cordyceps mycelium capsules, etc. In addition to the above products, the company has begun to operate the online chronic disease management platform - Yicheng Network Hospital, expanding its business to the downstream health service field. The Yicheng Network Hospital built by the company aims to use Internet technology to connect equipment with medical service resources and provide online personal comprehensive health management services for patients with chronic diseases. Since its establishment, Yicheng Bio has been committed to relying on continuous technological development to provide diverse and advanced rapid testing products to all sectors of society, constantly meeting human pursuit of health. The company's doctoral, master's and engineer teams carry out independent research and development work. The technical team members graduated from Tsinghua University, Peking University, Academy of Military Medical Sciences, University of Chinese Academy of Sciences, University of Bochum, University of Saskatchewan, and other well-known domestic and foreign universities. They have long been Engaged in the research and development of electrochemical biosensor technology, gold standard immunochromatography technology, biochip technology, biochemical analysis kits, antibody reagents and other fields. The company has complete independent intellectual property rights in various core technical links and owns a total of 26 patents.
Hangzhou Biotest Biotechnology Co., Ltd.
Hangzhou Weice Biotechnology Co., Ltd. is a high-tech enterprise located in Linping District, Hangzhou. Since its establishment in August 2013, it has been specialized in the research and development, production and sales of POCT products. Weice Biotech has always adhered to the development concept of "making health management within reach", committed to building an ecological system of "chronic disease management + rapid diagnosis + digital medical care", and strived to become a globally trusted smart POCT provider. Weice Biotechnology has established and maintained a quality management system that complies with the requirements of medical device production quality management specifications, the Appendix to the In vitro diagnostic reagents, (EN)ISO13485:2016, MDSAP includes the 21CFRPart820 requirements, and implements continuous measurement, analysis and Improvements to fully meet applicable regulations, standards and customer needs. At the same time, the product has been certified by many countries and regions such as China's NMPA, EU CE, and the US FDA. Weice Bio has been deeply engaged in overseas markets and has strong advantages. Its products have been exported to more than 100 countries and regions including the United States, Italy, Germany, Turkey, etc., and have been widely recognized by local customers. It has established overseas subsidies in the United States, Hong Kong and India. company. In the Chinese market, Weice Bio products are sold to nearly 900 secondary and above hospitals. Weice Biotech has strong technological research and development and innovation capabilities. The NB-IoT Internet of Things 5G blood glucose meter independently developed in January 2021 was successfully launched. Weice Bio attaches great importance to intellectual property protection and protects the company's intellectual property rights through trademark application, patent application and other means. At present, the company has hundreds of patents and software copyrights.
Hangzhou Biotest Biotechnology Co., Ltd.
Hangzhou Weice Biotechnology Co., Ltd. is a high-tech enterprise located in Linping District, Hangzhou. Since its establishment in August 2013, it has been specialized in the research and development, production and sales of POCT products. Weice Biotech has always adhered to the development concept of "making health management within reach", committed to building an ecological system of "chronic disease management + rapid diagnosis + digital medical care", and strived to become a globally trusted smart POCT provider. Weice Biotechnology has established and maintained a quality management system that complies with the requirements of medical device production quality management specifications, the Appendix to the In vitro diagnostic reagents, (EN)ISO13485:2016, MDSAP includes the 21CFRPart820 requirements, and implements continuous measurement, analysis and Improvements to fully meet applicable regulations, standards and customer needs. At the same time, the product has been certified by many countries and regions such as China's NMPA, EU CE, and the US FDA. Weice Bio has been deeply engaged in overseas markets and has strong advantages. Its products have been exported to more than 100 countries and regions including the United States, Italy, Germany, Turkey, etc., and have been widely recognized by local customers. It has established overseas subsidies in the United States, Hong Kong and India. company. In the Chinese market, Weice Bio products are sold to nearly 900 secondary and above hospitals. Weice Biotech has strong technological research and development and innovation capabilities. The NB-IoT Internet of Things 5G blood glucose meter independently developed in January 2021 was successfully launched. Weice Bio attaches great importance to intellectual property protection and protects the company's intellectual property rights through trademark application, patent application and other means. At present, the company has hundreds of patents and software copyrights.
Johnson & Johnson (China) Investment Co., Ltd.
Wenjie OneTouch was originally affiliated to Johnson & Johnson Group, a century-old international brand. It is a sub-brand of Johnson & Johnson, a subsidiary of the United States that specializes in the production of blood sugar monitoring products (JPY is referred to as Johnson & Johnson's blood sugar meter for short). Now Johnson & Johnson's blood sugar meter has been renamed Wenjie blood sugar meter. In 1987, the Wenjie OneTouch brand was born, becoming a milestone in the development history of pocket blood glucose meters. In 1994, Johnson & Johnson introduced Steady OneTouch to the Chinese market to help Chinese diabetic patients monitor and control blood sugar. Since entering the Chinese market, Wenjie OneTouch has not only been committed to continuously improving the research and development of blood sugar monitoring technology and new products, but also actively devotes itself to China's diabetes education industry. Wenjie OneTouch has established cooperative relationships with hospitals across the country to promote diabetes education; cooperates with medical associations in various provinces and cities to establish diabetes education centers; carry out self-monitoring education for diabetic patients, free diabetes diagnosis and other activities; and cooperate with the Diabetes Branch of the Chinese Medical Association , sponsors the National Diabetes Census and Diabetes Academic Conference to further popularize self-monitoring and management knowledge of diabetes. Wenjie OneTouch's contribution to China's diabetes industry has been unanimously recognized by professional medical staff and patients, and has now become a leader and innovator in the field of blood sugar monitoring. For more than 30 years, LifeScan, the manufacturer of Wenjie OneTouch products, has been unswervingly committed to improving the quality of life of patients with diabetes. In 2019, Lefscon Group, the manufacturer of Wenjie OneTouch products, set up its Asian headquarters in Shanghai, relying on Lefscon (Shanghai) Medical Equipment Co., Ltd. to provide services to patients with diabetes in the Asia-Pacific region. Currently, there are more than 122 million diabetes patients in China, accounting for nearly one-tenth of the population. The number of diabetes patients in China ranks first in the world. Faced with such a huge market and the urgent need for blood sugar monitoring products from patients, the various blood sugar monitoring products and management solutions provided by Lefscon can just meet the performance needs of patients. At the same time, the investment in the new headquarters demonstrates the strategic significance of the Chinese market to Lefscon, and the company's determination to continue to develop and enhance its leadership in this key region. For more than 40 years, Lefscon has been unswervingly paying attention to patients' blood sugar monitoring and management, and has made unremitting efforts in diabetes health knowledge, committed to improving the quality of life of diabetic patients. Today, Wenjie OneTouch continues to be at the forefront of R&D, promoting professional monitoring and management for diabetes, and continuously improving the research and development and creation of blood sugar monitoring technology and new products, with more than 20 million loyal users around the world. Wenjie OneTouch's contribution to the diabetes industry has been unanimously recognized by professional medical staff and patients at home and abroad.
Johnson & Johnson (China) Investment Co., Ltd.
Wenjie OneTouch was originally affiliated to Johnson & Johnson Group, a century-old international brand. It is a sub-brand of Johnson & Johnson, a subsidiary of the United States that specializes in the production of blood sugar monitoring products (JPY is referred to as Johnson & Johnson's blood sugar meter for short). Now Johnson & Johnson's blood sugar meter has been renamed Wenjie blood sugar meter. In 1987, the Wenjie OneTouch brand was born, becoming a milestone in the development history of pocket blood glucose meters. In 1994, Johnson & Johnson introduced Steady OneTouch to the Chinese market to help Chinese diabetic patients monitor and control blood sugar. Since entering the Chinese market, Wenjie OneTouch has not only been committed to continuously improving the research and development of blood sugar monitoring technology and new products, but also actively devotes itself to China's diabetes education industry. Wenjie OneTouch has established cooperative relationships with hospitals across the country to promote diabetes education; cooperates with medical associations in various provinces and cities to establish diabetes education centers; carry out self-monitoring education for diabetic patients, free diabetes diagnosis and other activities; and cooperate with the Diabetes Branch of the Chinese Medical Association , sponsors the National Diabetes Census and Diabetes Academic Conference to further popularize self-monitoring and management knowledge of diabetes. Wenjie OneTouch's contribution to China's diabetes industry has been unanimously recognized by professional medical staff and patients, and has now become a leader and innovator in the field of blood sugar monitoring. For more than 30 years, LifeScan, the manufacturer of Wenjie OneTouch products, has been unswervingly committed to improving the quality of life of patients with diabetes. In 2019, Lefscon Group, the manufacturer of Wenjie OneTouch products, set up its Asian headquarters in Shanghai, relying on Lefscon (Shanghai) Medical Equipment Co., Ltd. to provide services to patients with diabetes in the Asia-Pacific region. Currently, there are more than 122 million diabetes patients in China, accounting for nearly one-tenth of the population. The number of diabetes patients in China ranks first in the world. Faced with such a huge market and the urgent need for blood sugar monitoring products from patients, the various blood sugar monitoring products and management solutions provided by Lefscon can just meet the performance needs of patients. At the same time, the investment in the new headquarters demonstrates the strategic significance of the Chinese market to Lefscon, and the company's determination to continue to develop and enhance its leadership in this key region. For more than 40 years, Lefscon has been unswervingly paying attention to patients' blood sugar monitoring and management, and has made unremitting efforts in diabetes health knowledge, committed to improving the quality of life of diabetic patients. Today, Wenjie OneTouch continues to be at the forefront of R&D, promoting professional monitoring and management for diabetes, and continuously improving the research and development and creation of blood sugar monitoring technology and new products, with more than 20 million loyal users around the world. Wenjie OneTouch's contribution to the diabetes industry has been unanimously recognized by professional medical staff and patients at home and abroad.
Shandong Zhushi Pharmaceutical Group Co.,LTD
Shandong Zhushi Pharmaceutical Group is located in China. It has been in the industry of Medical Devices for over 20 years now.
Our company presents innovative products to you that including Medical Devices (Epidemic Prevention Products, Medical consumables, Medical Plaster & Medical Gel Products), Skin Care and Cosmetics, Health Food Products, etc.
Shandong Zhushi Pharmaceutical Group Co.,LTD
Shandong Zhushi Pharmaceutical Group is located in China. It has been in the industry of Medical Devices for over 20 years now.
Our company presents innovative products to you that including Medical Devices (Epidemic Prevention Products, Medical consumables, Medical Plaster & Medical Gel Products), Skin Care and Cosmetics, Health Food Products, etc.
Xuzhou Kailier Sauna Equipment CO.,LTD
**Company Background and History**
Xuzhou Kailier Sauna Equipment Co., Ltd. was established in 1995, specializing in the research, development and production of far-infrared sauna products, with nearly 30 years of experience in the industry. The company was founded by a well-known local furniture craftsman. With a deep understanding of product structure and appearance design, Kelier has gradually grown into a comprehensive enterprise integrating R&D, production and sales.
Over the years, we have improved our management level and production efficiency through systematization and informationization. Our customers are all over East Asia, Europe and America, and we have successfully penetrated into high standard markets such as Germany and Japan. Currently, our export share is mainly concentrated in Germany (50%), the United States (30%), South Korea (10%), and other markets account for 10%.
**Capacity and Market Adjustment**
Kailier has excellent production capacity, especially in the far-infrared footbath production line, with a monthly capacity of 12,000-15,000 units, mainly supplying the Korean market. Due to the recent economic downturn in the market leading to a decrease in orders, the company has decided to shift part of the production capacity of the footbath bucket production line to the pet product market in order to fill the capacity gap.
**Pet Product Development**
Kailier has systematically built its R&D team since 2013, focusing on new product development and technological innovation. The company has an advanced production management system, introduced MRP II type production management mode as early as 2014, and independently developed production management system to realize high efficiency production, accurate delivery prediction and smooth production flow. The monthly production capacity can reach 1,500-2,000 saunas (about 30 containers), and 12,000-15,000 footbath buckets or pet products. In recent years, the company has also introduced a number of automated and intelligent production equipment, which has significantly improved production efficiency and product quality.
**Department structure and Team**
Kailier has a perfect organizational structure, the coordinated operation of all departments to ensure efficient production and strict quality control of products:
【Foreign Trade Department and Domestic Trade Department】：Responsible for the development and maintenance of international and domestic markets respectively.
【Production Department】：Responsible for production planning and manufacturing process to ensure efficient operation.
[Follow-up Department]: Manage orders and customer communication to ensure accurate order processing and customer satisfaction.
【Quality Department】：Including 7 quality control professionals, responsible for product quality control and testing.
【Engineering Department】：Including 2 electrical engineers, 1 BOM engineer and 3 engineering structural engineers, responsible for product development and technical support.
【Incoming Material Inspection】: Strictly control the quality of raw materials.
【Design Department】: including 1 3D design engineer and 1 graphic designer, responsible for product appearance design and visual image.
【Documentation Department】: 1 single certificate specialist, responsible for the management of export-related documents.
【Capital & Finance Department】: Responsible for the company's financial management and resource planning to ensure financial health and rational allocation of resources to support the company's sustainable development.
**Informatization management and quality control**
The company adopts advanced ERP system for comprehensive management, covering all aspects of purchasing, production, sales, inventory and finance, ensuring real-time sharing of information and efficient operation of management. In terms of quality control, the company is equipped with large-scale experimental and testing equipment, and implements strict multiple inspection methods to ensure that the appearance and reliability of the products meet the high standards of the industry.
Xuzhou Kailier Sauna Equipment CO.,LTD
**Company Background and History**
Xuzhou Kailier Sauna Equipment Co., Ltd. was established in 1995, specializing in the research, development and production of far-infrared sauna products, with nearly 30 years of experience in the industry. The company was founded by a well-known local furniture craftsman. With a deep understanding of product structure and appearance design, Kelier has gradually grown into a comprehensive enterprise integrating R&D, production and sales.
Over the years, we have improved our management level and production efficiency through systematization and informationization. Our customers are all over East Asia, Europe and America, and we have successfully penetrated into high standard markets such as Germany and Japan. Currently, our export share is mainly concentrated in Germany (50%), the United States (30%), South Korea (10%), and other markets account for 10%.
**Capacity and Market Adjustment**
Kailier has excellent production capacity, especially in the far-infrared footbath production line, with a monthly capacity of 12,000-15,000 units, mainly supplying the Korean market. Due to the recent economic downturn in the market leading to a decrease in orders, the company has decided to shift part of the production capacity of the footbath bucket production line to the pet product market in order to fill the capacity gap.
**Pet Product Development**
Kailier has systematically built its R&D team since 2013, focusing on new product development and technological innovation. The company has an advanced production management system, introduced MRP II type production management mode as early as 2014, and independently developed production management system to realize high efficiency production, accurate delivery prediction and smooth production flow. The monthly production capacity can reach 1,500-2,000 saunas (about 30 containers), and 12,000-15,000 footbath buckets or pet products. In recent years, the company has also introduced a number of automated and intelligent production equipment, which has significantly improved production efficiency and product quality.
**Department structure and Team**
Kailier has a perfect organizational structure, the coordinated operation of all departments to ensure efficient production and strict quality control of products:
【Foreign Trade Department and Domestic Trade Department】：Responsible for the development and maintenance of international and domestic markets respectively.
【Production Department】：Responsible for production planning and manufacturing process to ensure efficient operation.
[Follow-up Department]: Manage orders and customer communication to ensure accurate order processing and customer satisfaction.
【Quality Department】：Including 7 quality control professionals, responsible for product quality control and testing.
【Engineering Department】：Including 2 electrical engineers, 1 BOM engineer and 3 engineering structural engineers, responsible for product development and technical support.
【Incoming Material Inspection】: Strictly control the quality of raw materials.
【Design Department】: including 1 3D design engineer and 1 graphic designer, responsible for product appearance design and visual image.
【Documentation Department】: 1 single certificate specialist, responsible for the management of export-related documents.
【Capital & Finance Department】: Responsible for the company's financial management and resource planning to ensure financial health and rational allocation of resources to support the company's sustainable development.
**Informatization management and quality control**
The company adopts advanced ERP system for comprehensive management, covering all aspects of purchasing, production, sales, inventory and finance, ensuring real-time sharing of information and efficient operation of management. In terms of quality control, the company is equipped with large-scale experimental and testing equipment, and implements strict multiple inspection methods to ensure that the appearance and reliability of the products meet the high standards of the industry.
Shanghai Jianzhen Medical Technology Co., Ltd.
Jianzhen completed the acquisition of Bayer Diabetes Care business through PHC in 2016, and handed over the business in China to Jianzhen China on June 1, 2016-Shanghai Jianzhen Medical Technology Co., Ltd. Jianzhen (Ascensia Diabetes Care Shanghai Co. Ltd.). Jianzhen China will continue to provide Bayer's previous sales and promotion of diabetes health care business products and related services. The product portfolio includes the world-famous CONTOUR blood sugar monitoring system series such as Baiankang and Baianjin. Ascensia Diabetes Care is a professional global diabetes management company committed to improving the health of diabetics to improve their quality of life. Jianzhen has more than 80 years of innovative diabetes management products and strong innovative R&D channels. Its global headquarters is located in Basel, Switzerland, and its blood sugar monitoring products are sold in 125 countries. Jianzhen China’s mission is to help diabetics through innovative solutions to simplify and improve their lives. In the future, Jianzhen will continue to be committed to the continuous research, innovation and development of new products to meet the daily challenges faced by diabetic patients.
Shanghai Jianzhen Medical Technology Co., Ltd.
Jianzhen completed the acquisition of Bayer Diabetes Care business through PHC in 2016, and handed over the business in China to Jianzhen China on June 1, 2016-Shanghai Jianzhen Medical Technology Co., Ltd. Jianzhen (Ascensia Diabetes Care Shanghai Co. Ltd.). Jianzhen China will continue to provide Bayer's previous sales and promotion of diabetes health care business products and related services. The product portfolio includes the world-famous CONTOUR blood sugar monitoring system series such as Baiankang and Baianjin. Ascensia Diabetes Care is a professional global diabetes management company committed to improving the health of diabetics to improve their quality of life. Jianzhen has more than 80 years of innovative diabetes management products and strong innovative R&D channels. Its global headquarters is located in Basel, Switzerland, and its blood sugar monitoring products are sold in 125 countries. Jianzhen China’s mission is to help diabetics through innovative solutions to simplify and improve their lives. In the future, Jianzhen will continue to be committed to the continuous research, innovation and development of new products to meet the daily challenges faced by diabetic patients.
Guangzhou Wanfu Biotechnology Co., Ltd. (stock code: 300482) was founded in 1992 and is headquartered in Guangzhou Science City. It was listed on the Shenzhen Stock Exchange GEM on June 30, 2015. Wanfu Bio's business is concentrated in the field of in vitro diagnosis under the medical device sector, specializing in the research and development, production and intelligent manufacturing, marketing and services of fast diagnostic reagents and supporting instruments of instant testing/bedside testing. It is a domestic POCT One of the leading companies. The products are sold to more than 140 countries and regions around the world and are widely used in clinical testing, critical and severe diseases, chronic disease management, primary medical care, epidemic monitoring, disaster rescue, on-site law enforcement and family personal health management. Wanfu Bio has successively won the National Torch Program Key High-tech Enterprise, National Enterprise Technology Center, National Bioengineering High-tech Industrialization Demonstration Base, National Intellectual Property Advantage Enterprise, World Health Organization PQ Certified Enterprise, and World Customs Organization AEO Senior Certified Enterprise. One of the domestic in vitro diagnostic reagent companies that have passed the on-site audit of the US FDA. The company currently has set up R&D centers in Guangzhou, Shenzhen, China, and San Diego, USA. It has more than 800 R&D personnel, all of which are professionals in the fields of biochemistry, clinical medicine, microelectronics technology, etc. The intensity of R&D investment and R&D team strength are both in the industry's advanced position. After 30 years of development, the company has built a relatively complete technology platform and product line, and is an enterprise with a wide range of technology platform layouts and rich product lines among domestic POCT enterprises. The company has existing immunocolloid gold technology platform, immunofluorescence technology platform, electrochemical technology platform, dry biochemical technology platform, chemiluminescence technology platform, molecular diagnostic technology platform, pathological diagnosis technology platform, as well as instrument technology platform and biological raw material platform, and Relying on the above nine technical platforms, a rich product line has been formed in the field of cardiovascular and cerebrovascular diseases, inflammation, tumors, infectious diseases, viral testing (drug abuse), eugenics and other testing fields. As of December 31, 2021, the company has obtained a total of 540 product registration certificates such as NMPA, FDA, CE, and Canadian MDALL, ranking among the top in the industry.
Wondfo Biotech Co., Ltd.
Guangzhou Wanfu Biotechnology Co., Ltd. (stock code: 300482) was founded in 1992 and is headquartered in Guangzhou Science City. It was listed on the Shenzhen Stock Exchange GEM on June 30, 2015. Wanfu Bio's business is concentrated in the field of in vitro diagnosis under the medical device sector, specializing in the research and development, production and intelligent manufacturing, marketing and services of fast diagnostic reagents and supporting instruments of instant testing/bedside testing. It is a domestic POCT One of the leading companies. The products are sold to more than 140 countries and regions around the world and are widely used in clinical testing, critical and severe diseases, chronic disease management, primary medical care, epidemic monitoring, disaster rescue, on-site law enforcement and family personal health management. Wanfu Bio has successively won the National Torch Program Key High-tech Enterprise, National Enterprise Technology Center, National Bioengineering High-tech Industrialization Demonstration Base, National Intellectual Property Advantage Enterprise, World Health Organization PQ Certified Enterprise, and World Customs Organization AEO Senior Certified Enterprise. One of the domestic in vitro diagnostic reagent companies that have passed the on-site audit of the US FDA. The company currently has set up R&D centers in Guangzhou, Shenzhen, China, and San Diego, USA. It has more than 800 R&D personnel, all of which are professionals in the fields of biochemistry, clinical medicine, microelectronics technology, etc. The intensity of R&D investment and R&D team strength are both in the industry's advanced position. After 30 years of development, the company has built a relatively complete technology platform and product line, and is an enterprise with a wide range of technology platform layouts and rich product lines among domestic POCT enterprises. The company has existing immunocolloid gold technology platform, immunofluorescence technology platform, electrochemical technology platform, dry biochemical technology platform, chemiluminescence technology platform, molecular diagnostic technology platform, pathological diagnosis technology platform, as well as instrument technology platform and biological raw material platform, and Relying on the above nine technical platforms, a rich product line has been formed in the field of cardiovascular and cerebrovascular diseases, inflammation, tumors, infectious diseases, viral testing (drug abuse), eugenics and other testing fields. As of December 31, 2021, the company has obtained a total of 540 product registration certificates such as NMPA, FDA, CE, and Canadian MDALL, ranking among the top in the industry.
Berlang Medical (Shanghai) International Trade Co., Ltd.
The Berlan Group was founded in 1839 in the Meltsonggen region of Germany, with more than 66,000 employees in 64 countries around the world. After nearly two centuries of ups and downs and silent inheritance by several generations, Berlan has become the world's advanced medical equipment, medical products and services provider today, committed to infusion, anesthesia, dialysis, neurosurgery, spinal surgery, Provide solutions in related treatment areas such as diabetes care, clinical nutrition, wound management, infection prevention, etc. By having constructive dialogue with customers and partners, Berlan continuously develops high-quality innovative products and services for the healthcare system, thereby protecting and improving the health of human beings around the world. In 1985, Berlan established a branch in Hong Kong, China and officially launched its business in Greater China. After more than 30 years of development, Berlan has seven independent legal entities in China, headquartered in Shanghai, with branches in major Chinese cities such as Beijing, Guangzhou, and Wuhan. Its business covers more than 70 cities across the country and is in Jiangsu. Suzhou and Zibo, Shandong have invested in the construction of large production bases.
Berlang Medical (Shanghai) International Trade Co., Ltd.
The Berlan Group was founded in 1839 in the Meltsonggen region of Germany, with more than 66,000 employees in 64 countries around the world. After nearly two centuries of ups and downs and silent inheritance by several generations, Berlan has become the world's advanced medical equipment, medical products and services provider today, committed to infusion, anesthesia, dialysis, neurosurgery, spinal surgery, Provide solutions in related treatment areas such as diabetes care, clinical nutrition, wound management, infection prevention, etc. By having constructive dialogue with customers and partners, Berlan continuously develops high-quality innovative products and services for the healthcare system, thereby protecting and improving the health of human beings around the world. In 1985, Berlan established a branch in Hong Kong, China and officially launched its business in Greater China. After more than 30 years of development, Berlan has seven independent legal entities in China, headquartered in Shanghai, with branches in major Chinese cities such as Beijing, Guangzhou, and Wuhan. Its business covers more than 70 cities across the country and is in Jiangsu. Suzhou and Zibo, Shandong have invested in the construction of large production bases.
Terumo (China) Investment Co., Ltd.
Import channels were interrupted during World War I, and Japanese medical scientists made efforts to localize the thermometers as their goal. In 1921, medical scientists led by Dr. Shibasaburo Kitari founded the Telmao Company. Since its establishment, Termau has inherited the innovative challenge spirit of Dr. Beili, implemented the company philosophy of "contributing to society through medical care", and is committed to delivering excellent innovative technologies to the medical site. Telmao Co., Ltd. was founded in 1921. Its products include disposable medical devices, blood transfusion tools series, pharmaceutical and nutritional medicine series, angiography and therapeutic catheter, medical electronic products series, artificial heart and lung product series, etc. Termau's products have been widely used in many countries and regions around the world. Termau's unique technology will make the medical process humanized and gentle. The application of Telmao's new technology can relieve pain and discomfort during medical treatment as much as possible. Telmau has always been committed to developing medical products that meet high standards, not only meeting high standards in terms of safety and precision, but also in maintaining patients' good recovery and quality of life. At present, Telmao has established two factories in Hangzhou and Changchun, China respectively. Termau will dedicate mild, easy-to-use healthcare products and technologies to the world in the 21st century. In order to strengthen the integrated management of R&D, production and sales in China, Telmao applied for the establishment of Telmao (China) Investment Co., Ltd. in August 2012, with a registered capital of US$30 million. According to the early business strategy, the sales ratio of domestic products will be gradually increased in the future. The establishment of Telmao (China) Investment Co., Ltd. has also taken a big step to integrating the Greater China Circle Management Model in the Mainland, Hong Kong, Macau and Taiwan markets.
Terumo (China) Investment Co., Ltd.
Import channels were interrupted during World War I, and Japanese medical scientists made efforts to localize the thermometers as their goal. In 1921, medical scientists led by Dr. Shibasaburo Kitari founded the Telmao Company. Since its establishment, Termau has inherited the innovative challenge spirit of Dr. Beili, implemented the company philosophy of "contributing to society through medical care", and is committed to delivering excellent innovative technologies to the medical site. Telmao Co., Ltd. was founded in 1921. Its products include disposable medical devices, blood transfusion tools series, pharmaceutical and nutritional medicine series, angiography and therapeutic catheter, medical electronic products series, artificial heart and lung product series, etc. Termau's products have been widely used in many countries and regions around the world. Termau's unique technology will make the medical process humanized and gentle. The application of Telmao's new technology can relieve pain and discomfort during medical treatment as much as possible. Telmau has always been committed to developing medical products that meet high standards, not only meeting high standards in terms of safety and precision, but also in maintaining patients' good recovery and quality of life. At present, Telmao has established two factories in Hangzhou and Changchun, China respectively. Termau will dedicate mild, easy-to-use healthcare products and technologies to the world in the 21st century. In order to strengthen the integrated management of R&D, production and sales in China, Telmao applied for the establishment of Telmao (China) Investment Co., Ltd. in August 2012, with a registered capital of US$30 million. According to the early business strategy, the sales ratio of domestic products will be gradually increased in the future. The establishment of Telmao (China) Investment Co., Ltd. has also taken a big step to integrating the Greater China Circle Management Model in the Mainland, Hong Kong, Macau and Taiwan markets.
